Kidney Precision Medicine Project Recruitment Sites (U01 Clinical Trial Not Allowed)

The Kidney Precision Medicine Project Recruitment Sites program is a federal funding opportunity administered by the National Institutes of Health under the U.S. Department of Health and Human Services. Specifically aligned with the mission of advancing biomedical research in kidney disease, this opportunity is part of a broader initiative to improve understanding of kidney function and disease progression through precision medicine approaches. The program is supported through a cooperative agreement mechanism, which indicates substantial involvement from the funding agency in project oversight and collaboration. The initiative contributes to national research priorities in health, particularly in the areas of chronic and acute kidney conditions. The primary purpose of this funding opportunity is to support recruitment sites that will enroll participants into a longitudinal biopsy cohort study focused on Acute Kidney Injury and Chronic Kidney Disease. These recruitment sites play a critical role in gathering patient data and biospecimens that contribute to a deeper understanding of disease heterogeneity and progression. The program emphasizes enrolling underrepresented populations, particularly individuals with Acute Kidney Injury, and encourages comprehensive phenotyping approaches that include clinical, physiological, and molecular data collection. Funding under this opportunity supports a range of research-related activities tied to participant recruitment and data collection. Allowable activities include conducting clinical biopsies with residual tissue available for research purposes, performing enhanced physiologic phenotyping, collecting repeat biopsies where appropriate, and expanding recruitment to pediatric populations. Additionally, the collection of healthy reference tissue is included to provide comparative data for research analysis. All funded sites are expected to actively participate in collaborative scientific discovery and contribute to open science initiatives, ensuring that data generated through the program are broadly accessible to the research community. Eligibility for this opportunity is broad and includes a variety of entity types such as state and local governments, institutions of higher education, nonprofit organizations with or without 501(c)(3) status, for-profit organizations, small businesses, and tribal entities. However, eligibility is limited to domestic applicants; foreign organizations and non-U.S. components of U.S. entities are not permitted to apply. This ensures alignment with federal research priorities and compliance with NIH funding policies. The application process requires submission through standard federal grant mechanisms, typically via Grants.gov. While specific application components are not detailed in the summary, applicants can expect to provide comprehensive research plans, institutional capabilities, and documentation demonstrating their ability to recruit and manage study participants effectively. The absence of a cost-sharing or matching requirement reduces the financial burden on applicants and broadens accessibility to eligible entities. The timeline for this opportunity is clearly defined, with applications opening upon posting on June 3, 2026, and closing on July 10, 2026. There are no pre-application requirements such as letters of intent indicated in the summary. The program anticipates making approximately eight awards, with total program funding estimated at four million dollars. Individual awards may reach up to four hundred fifty thousand dollars, though a minimum award floor is not specified. Applicants are encouraged to adhere strictly to submission deadlines, as late applications are typically not considered under federal grant policies. Contact for this opportunity is provided through the Division of Kidney, Urologic, and Hematologic Diseases at the National Institutes of Health, with an official program email available for inquiries. This channel supports applicants in resolving technical or administrative issues related to the application process. Overall, this funding opportunity represents a significant investment in kidney disease research infrastructure and collaborative scientific advancement.